ROR1
ROR1 is an embryonic receptor re-expressed by many cancers, used as an ADC address in lymphoma and breast cancer.
ROR1 is an oncofetal receptor tyrosine kinase-like protein. Zilovertamab vedotin (MK-2140) is in phase 3 in DLBCL. TNBC and NSCLC expression supports solid-tumour programmes.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ROR1 is an embryonic receptor re-expressed by many cancers, used as an ADC address in lymphoma and breast cancer.
- 1 · What it is
ROR1 is an embryonic receptor re-expressed by many cancers, used as an ADC address in lymphoma and breast cancer.
- 2 · What goes wrong in cancer
Wnt5a pseudo-kinase receptor; drives survival signalling in CLL and MCL.
- 3 · How drugs use it
1 product aims at ROR1: antibody-drug conjugates. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Biology
Wnt5a pseudo-kinase receptor; drives survival signalling in CLL and MCL.
- CLL
- Mantle cell lymphoma
- DLBCL
- TNBC
- NSCLC
How common it is, by cancer
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Chronic lymphocytic leukaemia | >90% | Surface expression | Wikipedia | |
| Triple-negative breast cancer | 40-60% | IHC, any expression | Wikipedia | |
| Diffuse large B-cell lymphoma | 30-50% | IHC, any expression | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Latest papers
topQuery for this target: (TITLE:"ROR1" OR ABSTRACT:"ROR1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ROR1, not a curated reading list.